文献速递艾滋病与性传播感染

睾酮治疗对跨性别男性及非二元性别者阴道微生物群的影响:一项前瞻性研究

The Impact of Testosterone Therapy on the Vaginal Microbiota of Transgender Men and Nonbinary People: A Prospective Study.
PubMed 文献 · J Infect Dis · 2025-01-01

该前瞻性研究纳入9名开始注射睾酮的跨性别男性及出生时指定女性性别的非二元性别者,每日自采阴道标本进行革兰染色和16S rRNA基因测序。睾酮启动后89%(8/9)出现至少一次阴道菌群失调,56%(5/9)发生偶发性细菌性阴道病(iBV),多数iBV发生在启动后20至40天。作者认为需更大样本研究进一步阐明睾酮对阴道微生物群的影响。

要点

  • 睾酮启动后89%(8/9)参与者出现至少一次阴道菌群失调,56%(5/9)发生iBV。
  • 发生iBV者多数在睾酮启动后20至40天之间出现。
  • 未发生iBV者常见CST I,发生iBV者常见CST IV-B。

核心结论

  • 大多数参与者出现阴道菌群失调,包括iBV。
  • 需要更大样本的额外研究来进一步阐明睾酮如何影响阴道微生物群。

研究设计与样本

  • 前瞻性研究,纳入年龄≥18岁、出生时指定女性性别、自我认同为跨性别男性或非二元性别、有意开始注射睾酮、阴道微生物群最佳且当前无性传播感染者。
  • 参与者在睾酮启动前7天及启动后90天每日自采阴道标本,用于阴道革兰染色和16S rRNA基因测序。
  • 阴道菌群失调和iBV分别定义为Nugent评分≥4或≥7,且各持续≥2天。
  • 2022年2月至2023年11月间共9名参与者入组。

主要发现

  • 睾酮启动后89%(8/9)参与者出现至少一次阴道菌群失调。
  • 56%(5/9)参与者发生iBV。
  • 发生iBV者多数在睾酮启动后20至40天之间发生。
  • 未发生iBV者最常见CST I,发生iBV者最常见CST IV-B。
  • 性活动和月经似乎也影响iBV的发生。

关键数值与推荐

  • 阴道菌群失调定义为Nugent评分≥4且持续≥2天。
  • iBV定义为Nugent评分≥7且持续≥2天。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更大样本的额外研究来进一步阐明睾酮如何影响阴道微生物群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Understanding the impact of testosterone on the vaginal microbiota of transgender men (TGM) and nonbinary people assigned female sex at birth over time is imperative as vaginal dysbiosis and incident bacterial vaginosis (iBV) may cause bothersome genital symptoms and increase human immunodeficiency virus/sexually transmitted infection (HIV/STI) acquisition risk. We investigated shifts in the composition of the vaginal microbiota over time in TGM initiating testosterone for gender-affirming hormone therapy, including development of vaginal dysbiosis and iBV. METHODS: Participants ages ≥18 years, assigned female sex at birth and reporting TGM or nonbinary identity, interested in starting injectable testosterone, demonstrating optimal vaginal microbiota, with no current STI(s) were enrolled. Participants self-collected daily vaginal specimens for 7 days prior to testosterone initiation and 90 days thereafter for vaginal Gram staining and 16S rRNA gene sequencing. Episodes of vaginal dysbiosis and iBV were defined as Nugent scores ≥4 or ≥7, respectively, each for ≥2 consecutive days. RESULTS: Between February 2022 and November 2023, 9 participants enrolled, 89% (8/9) developed ≥1 episode(s) of vaginal dysbiosis after testosterone initiation, and 56% (5/9) developed iBV. Among those who developed iBV, most did so between days 20 and 40 after testosterone initiation. Community state type (CST) I was found most often in participants who did not develop iBV and CST IV-B most often in participants who developed iBV. Sexual activity and menses also appeared to influence the development of iBV. CONCLUSIONS: The majority of participants developed vaginal dysbiosis including iBV. Additional studies with larger sample sizes are needed to further elucidate how testosterone impacts the vaginal microbiota.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Van Gerwen OT, Aaron KJ, Kay ES, et al. The Impact of Testosterone Therapy on the Vaginal Microbiota of Transgender Men and Nonbinary People: A Prospective Study. J Infect Dis. 2025. PMID: 40037329. doi:10.1093/infdis/jiaf114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。